Opioid-Induced Constipation Market Report

Global and Region Opioid-Induced Constipation Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：183
  • REPORT CODE：GMM975793
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

    The report details the trend, potential and market size of Opioid-Induced Constipation market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Opioid-Induced Constipationmarket, defines the market attractiveness level of Opioid-Induced Constipation market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Opioid-Induced Constipation industry, describes the types of Opioid-Induced Constipation market, the applications of major players and the market size, and deeply analyzes the current situation of the global Opioid-Induced Constipation market and the development prospects and opportunities of Opioid-Induced Constipation industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Opioid-Induced Constipation market in Chapter 13.

    By Player:

    • Mallinckrodt

    • Progenics Pharmaceuticals

    • Salix (Bausch Health)

    • GSK

    • Prestige

    • Daiichi Sankyo

    • AstraZeneca

    • Shionogi

    • Takeda Pharmaceuticals

    • Purdue Pharm

    • Sanofi

    • Nektar Therapeutics

    • Bayer

    By Type:

    • Methylnaltrexone Bromide

    • Lubiprostone

    • Naloxegol

    • Others

    By End-User:

    • Hospital

    • Pharmacy

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Opioid-Induced Constipation Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Opioid-Induced Constipation Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Opioid-Induced Constipation Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Opioid-Induced Constipation Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Opioid-Induced Constipation Market Analysis and Outlook to 2022

    • 7.1 Global Opioid-Induced Constipation Consumption (2017-2022)

    • 7.2 United States Opioid-Induced Constipation Consumption (2017-2022)

    • 7.3 Europe Opioid-Induced Constipation Consumption (2017-2022)

    • 7.4 China Opioid-Induced Constipation Consumption (2017-2022)

    • 7.5 Japan Opioid-Induced Constipation Consumption (2017-2022)

    • 7.6 India Opioid-Induced Constipation Consumption (2017-2022)

    • 7.7 South Korea Opioid-Induced Constipation Consumption (2017-2022)

    8 Region and Country-wise Opioid-Induced Constipation Market Analysis and Outlook to 2028

    • 8.1 Global Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.2 United States Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.3 Europe Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.4 China Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.5 Japan Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.6 India Opioid-Induced Constipation Consumption Forecast (2022-2028)

    • 8.7 South Korea Opioid-Induced Constipation Consumption Forecast (2022-2028)

    9 Global Opioid-Induced Constipation Market Outlook by Types and Applications to 2022

    • 9.1 Global Opioid-Induced Constipation Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Methylnaltrexone Bromide Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Lubiprostone Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Naloxegol Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Opioid-Induced Constipation Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pharmacy Consumption and Growth Rate (2017-2022)

    10 Global Opioid-Induced Constipation Market Outlook by Types and Applications to 2028

    • 10.1 Global Opioid-Induced Constipation Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Methylnaltrexone Bromide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Lubiprostone Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Naloxegol Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Opioid-Induced Constipation Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    11 Global Opioid-Induced Constipation Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Opioid-Induced Constipation Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Opioid-Induced Constipation Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Opioid-Induced Constipation Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Opioid-Induced Constipation Market Competitive Analysis

    • 14.1 Mallinckrodt

      • 14.1.1 Mallinckrodt Company Details

      • 14.1.2 Mallinckrodt Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Mallinckrodt Opioid-Induced Constipation Product and Service

    • 14.2 Progenics Pharmaceuticals

      • 14.2.1 Progenics Pharmaceuticals Company Details

      • 14.2.2 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Progenics Pharmaceuticals Opioid-Induced Constipation Product and Service

    • 14.3 Salix (Bausch Health)

      • 14.3.1 Salix (Bausch Health) Company Details

      • 14.3.2 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Salix (Bausch Health) Opioid-Induced Constipation Product and Service

    • 14.4 GSK

      • 14.4.1 GSK Company Details

      • 14.4.2 GSK Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 GSK Opioid-Induced Constipation Product and Service

    • 14.5 Prestige

      • 14.5.1 Prestige Company Details

      • 14.5.2 Prestige Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Prestige Opioid-Induced Constipation Product and Service

    • 14.6 Daiichi Sankyo

      • 14.6.1 Daiichi Sankyo Company Details

      • 14.6.2 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Daiichi Sankyo Opioid-Induced Constipation Product and Service

    • 14.7 AstraZeneca

      • 14.7.1 AstraZeneca Company Details

      • 14.7.2 AstraZeneca Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 AstraZeneca Opioid-Induced Constipation Product and Service

    • 14.8 Shionogi

      • 14.8.1 Shionogi Company Details

      • 14.8.2 Shionogi Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Shionogi Opioid-Induced Constipation Product and Service

    • 14.9 Takeda Pharmaceuticals

      • 14.9.1 Takeda Pharmaceuticals Company Details

      • 14.9.2 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Takeda Pharmaceuticals Opioid-Induced Constipation Product and Service

    • 14.10 Purdue Pharm

      • 14.10.1 Purdue Pharm Company Details

      • 14.10.2 Purdue Pharm Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Purdue Pharm Opioid-Induced Constipation Product and Service

    • 14.11 Sanofi

      • 14.11.1 Sanofi Company Details

      • 14.11.2 Sanofi Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Sanofi Opioid-Induced Constipation Product and Service

    • 14.12 Nektar Therapeutics

      • 14.12.1 Nektar Therapeutics Company Details

      • 14.12.2 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Nektar Therapeutics Opioid-Induced Constipation Product and Service

    • 14.13 Bayer

      • 14.13.1 Bayer Company Details

      • 14.13.2 Bayer Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Bayer Opioid-Induced Constipation Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Opioid-Induced Constipation

    • Figure Opioid-Induced Constipation Picture

    • Table Global Opioid-Induced Constipation Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Opioid-Induced Constipation Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Opioid-Induced Constipation Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Opioid-Induced Constipation Consumption by Country (2017-2022)

    • Figure United States Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Table Europe Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Figure China Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Figure Japan Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Figure India Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Figure South Korea Opioid-Induced Constipation Consumption and Growth Rate (2017-2022)

    • Figure Global Opioid-Induced Constipation Consumption Forecast by Country (2022-2028)

    • Figure United States Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Opioid-Induced Constipation Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Methylnaltrexone Bromide Consumption and Growth Rate (2017-2022)

    • Figure Global Lubiprostone Consumption and Growth Rate (2017-2022)

    • Figure Global Naloxegol Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Methylnaltrexone Bromide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lubiprostone Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Naloxegol Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Opioid-Induced Constipation Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Opioid-Induced Constipation Export by Region (Top 5 Countries) (2017-2028)

    • Table Mallinckrodt (Foundation Year, Company Profile and etc.)

    • Table Mallinckrodt Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mallinckrodt Opioid-Induced Constipation Product and Service

    • Table Progenics Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Progenics Pharmaceuticals Opioid-Induced Constipation Product and Service

    • Table Salix (Bausch Health) (Foundation Year, Company Profile and etc.)

    • Table Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Salix (Bausch Health) Opioid-Induced Constipation Product and Service

    • Table GSK (Foundation Year, Company Profile and etc.)

    • Table GSK Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Opioid-Induced Constipation Product and Service

    • Table Prestige (Foundation Year, Company Profile and etc.)

    • Table Prestige Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Prestige Opioid-Induced Constipation Product and Service

    • Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Opioid-Induced Constipation Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Opioid-Induced Constipation Product and Service

    • Table Shionogi (Foundation Year, Company Profile and etc.)

    • Table Shionogi Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shionogi Opioid-Induced Constipation Product and Service

    • Table Takeda Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Takeda Pharmaceuticals Opioid-Induced Constipation Product and Service

    • Table Purdue Pharm (Foundation Year, Company Profile and etc.)

    • Table Purdue Pharm Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Purdue Pharm Opioid-Induced Constipation Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Opioid-Induced Constipation Product and Service

    • Table Nektar Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nektar Therapeutics Opioid-Induced Constipation Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Opioid-Induced Constipation Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Opioid-Induced Constipation Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US